TICKERNERD
Menu
URGNURGNHealthcare · Biotechnology

URGN Stock Forecast: UroGen Pharma Ltd. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$48
+0.21% on the day

The 8 Wall Street analysts covering UroGen Pharma Ltd. hold a median 12-month price target of $59 — +22.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.3B
Ticker Nerd rank
83 / 100
Median analyst target
$59
Analysts covering
8
Total return, dividends reinvested
1W
+2.7%
1M
+23.0%
YTD
+105.9%
1Y
+140.1%
From 52W high
−1.6%
From 52W low
+193.7%
$16
$49
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

URGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores UroGen Pharma Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
83 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Growth
96
Value
93
Revisions
91
Quality
67
Volatility
66
Size
34
Accruals
13
Issuance
9

Momentum (99): The shares have been drifting up relative to others.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

URGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on URGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70$80Oct 25Jan 26Apr 26Jul 26URGNHigh $75Median $59Low $44

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $44Median $59High $75

The green dot is the last close — the median target sits +22.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Aug 2026GuggenheimMaintainsBuy$42 → $58
6 Aug 2026HC Wainwright & Co.MaintainsBuy$45 → $75
5 Aug 2026TD CowenMaintainsBuy$50 → $60
21 July 2026GuggenheimMaintainsBuy—
21 July 2026GuggenheimMaintainsBuy$32 → $42
16 July 2026OppenheimerMaintainsOutperformer$40 → $50
16 July 2026OppenheimerMaintainsOutperformer—
3 June 2026HC Wainwright & Co.ReiteratesBuy$45
3 June 2026HC Wainwright & Co.ReiteratesBuy—
18 May 2026HC Wainwright & Co.ReiteratesBuy—
11 May 2026HC Wainwright & Co.MaintainsBuy—
7 May 2026OppenheimerMaintainsOutperform—
31 Mar 2026D. Boral CapitalMaintainsBuy—
2 Mar 2026D. Boral CapitalMaintainsBuy—
23 Jan 2026D. Boral CapitalMaintainsBuy—
5 Jan 2026D. Boral CapitalMaintainsBuy—
27 Oct 2025D. Boral CapitalMaintainsBuy—
27 Oct 2025HC Wainwright & Co.ReiteratesBuy—
3 Oct 2025D. Boral CapitalMaintainsBuy—
19 Aug 2025Piper SandlerInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. URGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

URGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
0
Fundamentals

UroGen Pharma Ltd. (URGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−15.1×

Cheaper than 95% of US stocks

Price / sales
12.4×

Cheaper than 13% of US stocks

Price / book
−18.3×

Cheaper than 98% of US stocks

EV / EBITDA
−36.9×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
199.2%

Higher than 96% of US stocks

Earnings growth (YoY)
199.2%

Higher than 90% of US stocks

Gross margin
90.9%

Higher than 97% of US stocks

Operating margin
0.2%

Higher than 46% of US stocks

Net margin
−51.7%

Higher than 10% of US stocks

Returns & dividend
Return on equity
145.5%

Higher than 97% of US stocks

Return on assets
−18.1%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

URGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
URGNUroGen Pharma Ltd.$2.3B
83
NKTRNektar Therapeutics$2.4B
53
PHVSPharvaris NV$2.4B
40
MLYSMineralys Therapeutics, Inc.$2.3B
21
VRDNViridian Therapeutics, Inc.$2.4B
42
VCELVericel Corp.$2.2B
95
PVLAPalvella Therapeutics, Inc.$2.2B
33

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own UroGen Pharma Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest URGN news & analysis

Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice

Zacks Investment Research · 14 Aug 2026positive

A Zacks Investment Research article highlights Urogen Pharma (URGN) as a strong candidate for momentum investors, suggesting the stock has favorable characteristics for those seeking momentum-based opportunities.

Why it matters — URGN watchers would care because the article positions the company as a notable momentum pick, potentially drawing increased investor attention to the stock.

Urogen Pharma Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

Urogen Pharma reported second-quarter 2026 revenue of $72.5 million, up from $24.2 million a year earlier, as its bladder cancer treatment ZUSDURI gained commercial traction. Net loss narrowed to $14.4 million, or $0.28 per share, from $49.9 million, or $1.05 per share, in the prior-year quarter.

Why it matters — For URGN watchers, the quarter shows sharply higher revenue and a much narrower loss as the ZUSDURI launch continues to gain traction.

UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Seeking Alpha has published the transcript of UroGen Pharma Ltd.'s Q2 2026 earnings call. The item provides the record of management's remarks and discussion from the company's second-quarter earnings conference.

Why it matters — A URGN watcher would turn to this transcript to review the company's latest quarterly earnings commentary and management discussion in detail.

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 5 Aug 2026positive

Urogen Pharma reported a second-quarter loss of $0.28 per share, narrower than the Zacks Consensus Estimate of a $0.38 loss, and an improvement on the $1.05 per-share loss recorded a year ago. The company also topped revenue estimates for the quarter.

Why it matters — A smaller-than-expected loss and revenue beat may reassure URGN watchers about the company's improving financial trajectory.

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

GlobeNewsWire · 5 Aug 2026positive

UroGen reported $50.4 million in ZUSDURI revenue for the second quarter of 2026, a 73% quarter-over-quarter increase, and updated progress on its pipeline including UGN-103's planned NDA submission and UGN-501's upcoming Phase 1 trial. The company also noted a new U.S. patent expected to provide protection into July 2044 for ZUSDURI and UGN-103.

Why it matters — A URGN watcher would care because strong ZUSDURI revenue growth and extended patent protection strengthen the company's commercial foundation, while the advancing pipeline signals potential near-term catalysts. The conference call provides management's outlook.

FAQ

Frequently asked questions about URGN stock

What is the URGN stock price forecast for 2026-2027?

The 8 Wall Street analysts covering UroGen Pharma Ltd. have a median 12-month price target of $59, with estimates ranging from $44 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is URGN stock a buy right now?

Of the 8 analysts covering UroGen Pharma Ltd., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks UroGen Pharma Ltd. 83 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank URGN?

As at 15 Aug 2026, UroGen Pharma Ltd. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will URGN stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +22.4% from the last close, and Ticker Nerd's factor model ranks UroGen Pharma Ltd. 83 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the URGN stock forecast for 2030?

No analyst covering UroGen Pharma Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for URGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $75 over the next 12 months.

How has URGN stock performed over the past year?

UroGen Pharma Ltd. returned +140.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does UroGen Pharma Ltd. do?

UroGen Pharma Ltd. is an Israel-based biopharmaceutical company specializing in innovative treatments for urological cancers and diseases.

What is the latest news on URGN?

The most recent item we track (Zacks Investment Research, 14 Aug 2026): "Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice". A Zacks Investment Research article highlights Urogen Pharma (URGN) as a strong candidate for momentum investors, suggesting the stock has favorable characteristics for those seeking momentum-based opportunities.

Company

About UroGen Pharma Ltd.

UroGen Pharma Ltd. is an Israel-based biopharmaceutical company specializing in innovative treatments for urological cancers and diseases. The company develops therapies using its proprietary RTGel reverse-thermal hydrogel technology, a sustained-release platform that enhances drug delivery directly to targeted tissues in the urinary tract. Key FDA-approved products include Jelmyto, a mitomycin-based formulation for low-grade upper tract urothelial cancer, and Zusduri, designed for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. UroGen Pharma Ltd. also advances a pipeline of product candidates like MitoGel (UGN-101) and VesiGel (UGN-102), focusing on chemotherapy agents such as mitomycin C for various bladder and upper tract cancers. This technology addresses limitations of traditional treatments by enabling localized, prolonged exposure while minimizing systemic side effects. Operating in the pharmaceuticals and biotechnology sector, UroGen Pharma Ltd. plays a vital role in uro-oncology by providing non-surgical alternatives and expanding patient access to advanced bladder cancer therapies.

CEO Ms. Elizabeth A. Barrett · 300 employees · United States · https://www.urogen.com